Ardent Health, Inc. (NYSE:ARDT) Receives Average Rating of “Hold” from Analysts

Shares of Ardent Health, Inc. (NYSE:ARDT) have received an average rating of “Hold” from the thirteen research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $14.25.

A number of research analysts have commented on ARDT shares. Stephens cut their target price on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Friday, November 14th. Wall Street Zen cut shares of Ardent Health from a “buy” rating to a “hold” rating in a research note on Sunday, November 23rd. Leerink Partners dropped their price target on Ardent Health from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday. Mizuho cut their price objective on shares of Ardent Health from $20.00 to $12.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Finally, JPMorgan Chase & Co. reduced their price objective on Ardent Health from $12.00 to $11.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th.

More Ardent Health News

Here are the key news stories impacting Ardent Health this week:

• Neutral Sentiment: Independent valuation/market‑watch piece flags short‑term weakness and reviews ARDT’s valuation versus recent trading patterns and fundamentals. This is analytical context for investors but not new company guidance. Read More.
• Negative Sentiment: A formal class action securities lawsuit was announced against Ardent covering July 18, 2024–Nov 12, 2025; the complaint alleges securities fraud tied to the company’s revenue/receivable accounting disclosures. Litigation increases legal/financial risk and can pressure the stock. Read More.
• Negative Sentiment: Multiple plaintiff firms (Hagens Berman, Faruqi & Faruqi, Schall, Rosen, Bragar, Bronstein, DJS, etc.) are actively soliciting plaintiffs and reminding investors of the March 9, 2026 lead‑plaintiff deadline. The publicity can amplify selling pressure and increase the likelihood of consolidated litigation and discovery costs. The suit centers on a Nov. 2025 disclosure about a rigid “180‑day cliff” reserve method for uncollectible accounts. Read More.
• Negative Sentiment: Leerink Partners trimmed its price target to $15, signaling reduced analyst conviction and lowering near‑term upside expectations. Analyst downgrades/target cuts can weigh on sentiment. Read More.

Institutional Investors Weigh In On Ardent Health

Several hedge funds have recently bought and sold shares of ARDT. Caitong International Asset Management Co. Ltd increased its holdings in shares of Ardent Health by 1,177.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock valued at $25,000 after purchasing an additional 2,638 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Ardent Health during the third quarter valued at $61,000. Monetary Solutions Ltd purchased a new position in Ardent Health in the fourth quarter valued at $79,000. KLP Kapitalforvaltning AS purchased a new position in Ardent Health in the third quarter valued at $80,000. Finally, New York State Common Retirement Fund raised its position in shares of Ardent Health by 121.4% in the second quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock worth $85,000 after acquiring an additional 3,400 shares during the period.

Ardent Health Stock Up 2.6%

Shares of NYSE ARDT opened at $9.13 on Tuesday. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of 9.51 and a beta of 0.45. Ardent Health has a 12-month low of $8.07 and a 12-month high of $15.48. The firm’s 50-day moving average price is $9.00 and its 200-day moving average price is $10.95. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67.

Ardent Health (NYSE:ARDT) last announced its earnings results on Wednesday, March 4th. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03). Ardent Health had a net margin of 2.15% and a return on equity of 14.46%. The firm had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.63 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. On average, equities research analysts anticipate that Ardent Health will post 1.23 EPS for the current fiscal year.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.